Search Results
Emerging salvage therapies for BCG-unresponsive non-muscle invasive bladder cancer
BCG Unresponsive Non-Muscle Invasive Bladder Cancer
Controversies in Non-muscle Invasive Bladder Cancer (NMIBC): Guidelines and Beyond 2023
Management of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Second line Bladder Cancer Therapies When First Line Treatments Fail
Management of BCG Unresponsive Cystectomy Ineligible Bladder Cancer Patients Pembrolizumab
Immunotherapy as Salvage Treatment for Non-Muscle-Invasive Bladder Cancer
Novel Therapies to Non Muscle Invasive Bladder Cancer
Management of Non Muscle Invasive Bladder Cancer Webcast (2021)
Adaptive Immune Resistance to Intravesical BCG in NMIBC: BCG-Unresponsive Clinical Trials
Scott Tagawa, MD, on the study investigating Nadofaragene firadenovec in BCG unresponsive NMIBC
Dr. Ramos on the Role of BCG In Non-Muscle Invasive Bladder Cancer
